103321966 : On December 12, 2024, Keros Therapeutics, Inc. (the “Company”) announced that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension, based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial. A

Who Am I : Sure a????

JiuShini OP : No more overreaction play, don't be greedy n gamble, only OTLK n APLT were lucky cases, the rest like RLMD>BIOA>CLRB>SFHG all declined further, so don't expect in overreaction ticker anymore.